regn5459
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 26, 2019 (NCT04083534)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFRSF17 adcc
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314788 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06975787 | Phase 1 | Nov 6, 2025 | Regeneron |
| NCT05092347 | Phase 1/Phase 2 (Phase 2) | Jan 11, 2022 | Regeneron |
| NCT04083534 | Phase 1 | Sep 26, 2019 | Regeneron |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 3 | 3 | 2 | 2019 |
1 organizations
Page 1 / 1